) revealed that its new CyberKnife M6 Series and TomoTherapy H
Series Systems are steadily gaining market share worldwide. This
announcement was made by the company at the 55th Annual American
Society for Radiation Oncology (ASTRO) meeting being held at the
Georgia World Congress Center in Atlanta.
The two new treatment platforms were launched by ARAY last year.
Knowledge on the clinical capabilities on the same can be derived
through presentations to be delivered by leading radiation
oncology practitioners during the ASTRO meeting.
ARAY informed that many cancer centers in the U.S. as well as in
Europe have already invested in the technology, contributing to
the consistent adoption and growth of the company's advanced line
Some of the U.S. centers that have started to invest in such new
age product platforms include the University of Pittsburgh
Medical Center and Lancaster General Health in PA, Tulsa Cancer
Institute of Oklahoma, Spokane CyberKnife & Radiation
Oncology Center in Wash and University of Arkansas Medical
Sciences in Little Rock, AR.
Centers in Europe and Asia include, the European CyberKnife
Center Munich-Grosshadern (ECZM) in Munich, and Heidelberg
University Hospital in Germany. Erasmus Medical Center (MC), in
Rotterdam, the Netherlands; the Centre Oscar Lambret in Lille
France; and The Severance Hospital, Yonsei University Healthcare
System in Seoul, Korea.
Healthcare experts at the Barshinger Cancer Institute of
Lancaster General Health in Pennsylvania have welcomed the new
CyberKnife M6 System as its unique non-coplanar beam geometry
helps to create high-quality, high-dose distributions. This
guarantees high accuracy levels and minimizes side effects, thus
improving and retaining the quality of patient's
They are keen about providing the most effective and efficient
SRS/SBRT treatment option and believe that they can benefit from
the CyberKnife System which can track and treat moving targets
without affecting nearby critical structures and healthy tissue.
ACCURAY INC (ARAY): Free Stock Analysis
CYNOSURE INC-A (CYNO): Free Stock Analysis
DELCATH SYS INC (DCTH): Free Stock Analysis
ECHO THERAPEUT (ECTE): Free Stock Analysis
To read this article on Zacks.com click here.
Experts at the Centre Oscar Lambret, Lille, France note that
within the first three months of clinical use of the TomoHDA
System at their center, they have achieved significant results.
Rapid treatment planning and high-precision dose delivery are
characteristics that are well compatible for treatment of breast
cancer and helps improve overall quality, patient throughput and
workflow for the department.
ARAY seeks to provide better and advanced treatment services to
patients and continuously tries to enhance the capabilities of
the TomoTherapy and CyberKnife Systems. In this regard, ARAY
values the feedback received from leading radiation oncology
practitioners who have collaborated with the company and relies
on such positive relationships to build their product portfolio
Currently, ARAY carries a Zacks Rank #3 (Hold). Other stocks in
the medical instrument industry include
Delcath Systems, Inc.
Echo Therapeutics, Inc.
), each of which carries a Zacks Rank #2 (Buy).